Are you ready for the next massive leap in regenerative aesthetics? In this episode of Beauty Bytes, I am joined by Dr. Samuel Lynch, the founder and CEO of Lynch Regenerative Medicine and a translational scientist who has spent 30 years pioneering tissue regeneration. We dive deep into the science of Platelet-Derived Growth Factor (PDGF) and his groundbreaking product, Ariessence.

Dr. Lynch explains why PDGF remains the only single, pure growth factor to receive FDA approval—achieving this milestone four times across various medical applications, including the treatment of severe diabetic foot ulcers. We discuss why pharmaceutical-grade PDGF is exponentially more reliable than traditional Platelet-Rich Plasma (PRP), delivering a pure, consistent dose that is 1,000 to 300,000 times more concentrated than the unpredictable platelets harvested from a patient’s own blood. PDGF acts as the body’s ultimate wound-healing molecule, stimulating the production of collagen types 1, 3, and 6, natural hyaluronic acid, elastin, and new blood vessels.

We also tackle the recent social media controversies surrounding off-label use head-on. Dr. Lynch shares two massive announcements: the completion of a real-world evidence study showing zero serious adverse events across 3,000 treatments, and the FDA’s approval of an Investigational New Drug (IND) application to begin a Phase 2b clinical trial for injecting PDGF into infraorbital (under-eye) hollows. Plus, we cover their recent clinical trials utilizing PDGF for healing Mohs surgery defects.

Guest Information: Dr. Samuel Lynch is the CEO of Lynch Regenerative Medicine. You can learn more about Ariessence and find a provider at ariessence.com or lynchregen.com.